Zeposia (ozanimod) 0.92 mg, a new once-daily oral medication for adults for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, is now commercially available in the U.S. 

The Zeposia 360 Support program will facilitate access to Zeposia for appropriate patients with MS. This includes a copay of as little as $0 for eligible appropriate patients, assistance with financial support, reimbursement for some initial out-of-pocket medical costs – and a program that may help eligible patients with commercial insurance to receive free medication while they are waiting for insurance approvals. Terms, conditions, and eligibility criteria apply. 

Before initiation of treatment with Zeposia, discuss treatment options with your doctor. For more information visit Zeposia.com.